Recent events
Recent events tied to this brand in public sources.
Back to profile1 entries
2023
FDA approves Krystal Biotech's Vyjuvek gene therapy
The US Food and Drug Administration approved Krystal Biotech's Vyjuvek, a topical gene therapy for dystrophic epidermolysis bullosa (DEB).